Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

KITTEE (KTE) TRC20 Token

AVXL News and Press Anavex Life Sciences Corp.


home / stock / avxl / avxl news

RSS
AVXL AVXL Quote AVXL Short AVXL News AVXL Articles AVXL Message Board
  • Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi Approved

    Summary FDA grants emergency approval of Biogen/Eisai's Leqembi (previously Lecanemab), based solely on Phase 2 trial results; Phase 3 results to be considered for final approval. Anavex Life Sciences produces the alternative Alzheimer's drug Blarcamesine, which appears more effective, ...

    • January 30, 2023 12:13:54 pm
    • |
    • SeekingAlpha
    • |
      • AVXL Stock
      • AVXL Quote
      • AVXL Short
      • AVXL News
      • AVXL Articles
      • AVXL Message Board
  • Healthcare Outlook 2023

    Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

    • January 23, 2023 10:02:02 am
    • |
    • SeekingAlpha
    • |
      • AVXL Stock
      • AVXL Quote
      • AVXL Short
      • AVXL News
      • AVXL Articles
      • AVXL Message Board
  • 3 Biotech Stocks Under $15 Worth a Second Look in 2023

    A stock that trades at $15 or less isn't necessarily a bargain. Often, a stock trading that low is risky and anything but a bargain. However, biotech stocks Novavax (NASDAQ: NVAX) , MannKind (NASDAQ: MNKD) , and Anavex Life Sciences (NASDAQ: AVXL) all trade at $15 or l...

    • January 18, 2023 08:00:00 am
    • |
    • Motley Fool
    • |
      • AVXL Stock
      • AVXL Quote
      • AVXL Short
      • AVXL News
      • AVXL Articles
      • AVXL Message Board
  • Anavex: Drug Treatments For Early Alzheimer's Disease

    Summary Anavex 2-73/blarcamesine at high concentrations in early Alzheimer's disease leads to improvements in cognition and activities of daily living that are largely sustained for 148 weeks in most individuals. Alzheon's ALZ-801 reduces cognitive decline in ApoE4 carriers by about the...

    • January 17, 2023 05:10:52 pm
    • |
    • SeekingAlpha
    • |
      • AVXL Stock
      • AVXL Quote
      • AVXL Short
      • AVXL News
      • AVXL Articles
      • AVXL Message Board
  • Anavex: Despite Positive Spin, No Clarity On Anomalies

    Summary Anavex Life Sciences Corp. presented solid-looking Alzheimer's data last month. Critics found a number of anomalies, some more real than others. Anavex Life Sciences management hasn't yet presented responses to these questions. Although the company posted ...

    • January 12, 2023 10:49:39 am
    • |
    • SeekingAlpha
    • |
      • AVXL Stock
      • AVXL Quote
      • AVXL Short
      • AVXL News
      • AVXL Articles
      • AVXL Message Board
  • Eisai And Biogen's Lecanemab: A Flawed Treatment For Alzheimer's Disease

    Summary Lecanemab only significantly slows down the progression of Alzheimer's disease in APOE4 carriers. Lecanemab is suspected of causing at least three deaths. The FDA may still grant approval to lecanemab with a warning label regarding brain bleeds and brain swelling. Medica...

    • December 30, 2022 05:22:04 pm
    • |
    • SeekingAlpha
    • |
      • AVXL Stock
      • AVXL Quote
      • AVXL Short
      • AVXL News
      • AVXL Articles
      • AVXL Message Board
  • Biogen's Alzheimer's Drug Likely To Be Approved With Warning Labels

    Summary A new as-yet-unreported death among those taking Biogen's Lecanemab in an extended post-Phase 3 study has emerged. Biogen's Lecanemab has a PDUFA date of January 6, 2023; the FDA will announce its preliminary (or final) approval or rejection. Six days later, Anavex Life Scie...

    • December 29, 2022 01:41:37 pm
    • |
    • SeekingAlpha
    • |
      • AVXL Stock
      • AVXL Quote
      • AVXL Short
      • AVXL News
      • AVXL Articles
      • AVXL Message Board
  • Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why

    Can a biotech stock that's down by about 40% in the last month have any chance of rallying to multiply in value by a factor of five over the next two years? Prospective investors looking for a big catch may be tempted to look to Anavex Life Sciences , (NASDAQ: AVXL) a clinical-stage drug ...

    • December 17, 2022 09:15:00 am
    • |
    • Motley Fool
    • |
      • AVXL Stock
      • AVXL Quote
      • AVXL Short
      • AVXL News
      • AVXL Articles
      • AVXL Message Board
  • Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer's Trial

    NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...

    • December 14, 2022 07:00:00 am
    • |
    • GlobeNewswire
    • |
      • AVXL Stock
      • AVXL Quote
      • AVXL Short
      • AVXL News
      • AVXL Articles
      • AVXL Message Board
  • Is Anavex Life Sciences a Buy?

    As a pre-revenue biotech company that's approaching decisive clinical and regulatory milestones, Anavex Life Sciences (NASDAQ: AVXL) isn't an investment for the faint of heart. It has no products on the market, and its share price is, for now, entirely dependent on how much the results of...

    • December 13, 2022 09:45:00 am
    • |
    • Motley Fool
    • |
      • AVXL Stock
      • AVXL Quote
      • AVXL Short
      • AVXL News
      • AVXL Articles
      • AVXL Message Board
Next 10
Stock Information

Anavex Life Sciences Corp. Company Name:

AVXL Stock Symbol:

NASDAQ Market:

Anavex Life Sciences Corp. Website:

Anavex Life Sciences Corp. Logo

Get AVXL Alerts

News, Short Squeeze, Breakout and More Instantly...

Ad

KITTEE (KTE) TRC20 Token
RECENT AVXL NEWS
  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Coins
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your Twitter Account

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.



Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

Follow @marketwirenews

| Facebook

| Telegram

| LinkedIn

| Reddit

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2023 Market Wire News